Literature DB >> 23661283

Effects of repeated dosing with mirtazapine, trazodone, or placebo on driving performance and cognitive function in healthy volunteers.

Kazumi Sasada1, Kunihiro Iwamoto, Naoko Kawano, Kunihiro Kohmura, Maeri Yamamoto, Branko Aleksic, Kazutoshi Ebe, Yukihiro Noda, Norio Ozaki.   

Abstract

OBJECTIVE: This study aimed to evaluate the effects of repeated treatments with the sedative antidepressants mirtazapine and trazodone on driving performance and cognitive function.
METHODS: Nineteen healthy men received continuous nocturnal doses of 15-mg mirtazapine , 25-mg trazodone, or placebo for 8 days in a double-blinded, three-way crossover trial. Subjects were asked to perform three driving tasks (road tracking, car following, and harsh braking) using a driving simulator and cognitive tasks (the Wisconsin Card Sorting Test, Continuous Performance Test, and N-back Test) at baseline and on Days 2 and 9. Stanford Sleepiness Scale scores were also assessed.
RESULTS: Mirtazapine significantly increased the standard deviation of lateral position in the road-tracking task as compared with trazodone on Day 2. Mirtazapine significantly increased Stanford Sleepiness Scale scores as compared with trazodone and placebo. For the remaining tasks, no significant effects of treatment were observed.
CONCLUSIONS: Acute treatment of mirtazapine impaired road-tracking performance and increased sleepiness, but sedative effects disappeared under repeated administrations. Trazodone did not affect driving performance or cognitive function under acute or repeated administrations. Both initial sedative effects and pharmacological profiles should be taken into consideration when using sedative antidepressants.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23661283     DOI: 10.1002/hup.2321

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  6 in total

Review 1.  The prevalence, measurement, and treatment of the cognitive dimension/domain in major depressive disorder.

Authors:  Roger S McIntyre; Holly X Xiao; Kahlood Syeda; Maj Vinberg; Andre F Carvalho; Rodrigo B Mansur; Nadia Maruschak; Danielle S Cha
Journal:  CNS Drugs       Date:  2015-07       Impact factor: 5.749

2.  The effects of acute treatment with ramelteon, triazolam, and placebo on driving performance, cognitive function, and equilibrium function in healthy volunteers.

Authors:  Akemi Miyata; Kunihiro Iwamoto; Naoko Kawano; Kunihiro Kohmura; Maeri Yamamoto; Branko Aleksic; Kazutoshi Ebe; Akiko Noda; Yukihiro Noda; Shuji Iritani; Norio Ozaki
Journal:  Psychopharmacology (Berl)       Date:  2014-12-24       Impact factor: 4.530

3.  Effects of Trazodone on Sleep Quality and Cognitive Function in Arteriosclerotic Cerebral Small Vessel Disease Comorbid With Chronic Insomnia.

Authors:  Jihui Wang; Sanxin Liu; Chongbang Zhao; Hongying Han; Xiaodong Chen; Jiong Tao; Zhengqi Lu
Journal:  Front Psychiatry       Date:  2020-06-30       Impact factor: 4.157

4.  Chronic dosing with mirtazapine does not produce sedation in rats.

Authors:  Alberto Salazar-Juárez; Susana Barbosa-Méndez; Paola Merino-Reyes; Maura Matus-Ortega; Jorge A Hernández-Calderón; Benito Antón
Journal:  Braz J Psychiatry       Date:  2017-03-23       Impact factor: 2.697

5.  The effects of trazodone on human cognition: a systematic review.

Authors:  Ana Mafalda Gonçalves Gonçalo; Maria Augusta Vieira-Coelho
Journal:  Eur J Clin Pharmacol       Date:  2021-06-07       Impact factor: 2.953

6.  Low-Dose Mirtazapine-Induced Nightmares Necessitating its Discontinuation in a Young Adult Female.

Authors:  Vikas Menon; Pravallika Madhavapuri
Journal:  J Pharmacol Pharmacother       Date:  2017 Oct-Dec
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.